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The molecular basis of thymocyte negative selection, a crucial mechanism in establishing 
central tolerance, is not yet resolved. Histone deacetylases (HDACs) have emerged as key 
transcriptional regulators in several major developmental programs. Recently, we showed 
that the class IIa member, HDAC7, regulates negative selection by repressing expression of 
Nur77, an orphan nuclear receptor involved in antigen-induced apoptosis of thymocytes. 
Engagement of the T cell receptor (TCR) alleviates this repression through phosphorylation-
dependent nuclear exclusion of HDAC7. However, the identity of the TCR-activated kinase 
that phosphorylates and inactivates HDAC7 was still unknown. Here, we demonstrate that 
TCR-induced nuclear export of HDAC7 and Nur77 expression is mediated by activation of 
protein kinase D (PKD). Indeed, active PKD stimulates HDAC7 nuclear export and Nur77 
expression. In contrast, inhibition of PKD prevents TCR-mediated nuclear exclusion of 
HDAC7 and associated Nur77 activation. Furthermore, we show that HDAC7 is an 
interaction partner and a substrate for PKD. We identify four serine residues in the NH
 
2 
 
terminus of HDAC7 as targets for PKD. More importantly, a mutant of HDAC7 specifically 
deficient in phosphorylation by PKD, inhibits TCR-mediated apoptosis of T cell hybridomas. 
These findings indicate that PKD is likely to play a key role in the signaling pathways 
controlling negative selection.
 
For many cell surface receptors, ligation ini-
tiates a cascade of intracellular events that can
result in multiple cellular outcomes, depending
on the extent of the ligation and the cell con-
text. Nowhere is this more relevant than during
T cell development in the thymus. Mature
CD4
 
  
 
and CD8
 
  
 
T lymphocytes develop in
the thymus from a pool of CD4
 
  
 
CD8
 
  
 
double
positive (DP) precursors. These precursors
harbor diverse clonally distributed receptors
with negligible, intermediate, or high affinity
for self-peptide MHC complexes (1). Most DP
die “by neglect” as they fail to receive a signal
from their TCR. Cells receiving strong intra-
cellular signaling through engagement of their
TCR are eliminated by an activation-induced
apoptotic program termed negative selection,
which allows for deletion of autoreactive T
cells and establishment of central immune tol-
erance. In contrast, the small proportion of DP
thymocytes that display intermediate reactivity
for MHC ligands will receive an appropriate
signal allowing for survival and further differ-
entiation, a process named positive selection
(2). As a first step toward the comprehension
of these differentiative steps, a key issue is to
unravel TCR signaling pathways.
Engagement of the TCR results in the acti-
vation of several downstream cascades, involving
protein tyrosine kinases, protein kinase C (PKC),
and mitogen-activated protein kinases (3).
These signaling pathways ultimately induce
the activation and/or synthesis of transcription
factors, leading to changes in gene expression
and activation of specific developmental pro-
grams (4). The orphan nuclear receptor Nur77
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(also called TR3, NGFI-B, NAK1, Nr4a1, and several other
aliases) is a potent transcription factor that plays a key role in
negative selection (5). Thymocytes from Nur77-expressing
transgenic mice show massive cell death in vivo (6–8). In
contrast, loss of Nur77 function through overexpression of a
dominant negative mutant inhibits negative selection (9).
Although basal levels of Nur77 are extremely low in un-
stimulated T cells, engagement of the TCR induces rapid in-
duction of Nur77. The two major signaling pathways down-
stream of the TCR (the PKC pathway and the calcium
pathway) converge on the Nur77 promoter. Indeed, both
phorbol esters (for PKC) and ionomycin (for the Ca
 
2
 
  
 
path-
way) can activate Nur77 expression independently or in com-
bination (7). Transcriptional regulation of Nur77 is mediated
by two MEF2-binding sites located in the Nur77 promoter.
Cabin-1, a MEF2-interacting partner, was previously shown
to inhibit Nur77 expression and confer Ca
 
2
 
  
 
inducibility to
the Nur77 promoter (10). We have recently reported that
histone deacetylase (HDAC)7, a class IIa HDAC highly ex-
pressed in DP thymocytes, associates with MEF2D and re-
presses Nur77 expression via its deacetylase activity (11).
By modulating the accessibility of the transcriptional ma-
chinery to DNA, acetylation and deacetylation of nucleoso-
mal histones have emerged as key regulatory mechanisms of
gene transcription. Deacetylation of histones by HDACs re-
sults in a compact chromatin structure associated with tran-
scriptional repression. The 18 human HDACs identified to
date are grouped into four distinct classes, with members of
class II further subdivided into two subclasses, IIa (HDAC4,
HDAC5, HDAC7, and HDAC9) and IIb (HDAC6 and
HDAC10; reference 12).
Class IIa HDACs are restricted to a limited number of
cell types, suggesting a role for these proteins in specific bio-
logical processes. The class IIa HDACs contain two do-
mains: a conserved catalytic region at their COOH terminus
and an NH
 
2
 
-terminal extension showing limited sequence
homology amongst the different members. The NH
 
2
 
-termi-
nal domain of class IIa HDACs contains a conserved amino
acid motif implicated in interactions with members of the
MEF2 family of transcription factors. This interaction leads
to repression of MEF2-targeted promoters via recruitment of
class IIa–associated HDAC activity (13). In addition, the
NH
 
2
 
-terminal region of class IIa HDACs contains serine res-
idues important for their regulation (14). Sequence analysis
previously identified these serine residues as putative targets
for Ca
 
2
 
 
 
/calmodulin-dependent kinases (CaMKs). Phos-
phorylation of these residues by CaMK signaling leads to the
dissociation of MEF2 interactions and binding of 14-3-3
proteins, which induce class IIa HDAC nuclear export and
derepression of their target promoters (14–17). These find-
ings have been illustrated for HDAC5 and HDAC9 in the
context of the gene expression programs associated with
muscle differentiation (18) and cardiac hypertrophy (19). In
developing T cells, we recently reported that HDAC7 in-
hibits negative selection of DP thymocytes by repressing the
transcriptional activity of the Nur77 promoter (11). Upon
stimulation of the TCR, the inhibitory effect of HDAC7 is
relieved through its nuclear exclusion, allowing for Nur77
expression and engagement of negative selection programs.
In this report, we have examined the signaling pathways
leading to the nuclear exclusion and inactivation of HDAC7
during negative selection. We show that Ca
 
2
 
  
 
signaling
is not involved in TCR-mediated nuclear exclusion of
HDAC7. In contrast, we demonstrate that protein kinase D
(PKD; also known as PKC
 
 
 
), which is activated upon en-
gagement of the TCR, stimulates HDAC7 nuclear export
by direct phosphorylation on four serine residues. Con-
versely, selective PKD inhibition blocks TCR-induced
HDAC7 nuclear export and Nur77 expression. In addition,
an HDAC7 mutant specifically deficient in phosphorylation
by PKD blocks TCR-mediated apoptosis. These findings es-
tablish a key role for PKD in the signaling pathway mediat-
ing TCR-induced apoptosis in developing thymocytes and
indicate that PKD is likely to play an important role in the
control of central immune tolerance.
 
RESULTS
TCR-dependent nuclear export of HDAC7 is regulated by 
a PMA-stimulated, Gö6976-sensitive kinase
 
Our previous results have shown that TCR stimulation of T
cell hybridomas, a convenient model to study the molecular
aspects of negative selection in vitro (6, 10), induces rapid
and sustained relocalization of HDAC7 to the cytoplasm
(11). The signals downstream of the TCR consist of two in-
tracellular signaling pathways: the PKC pathway, which can
be mimicked by the addition of PMA, and the Ca
 
2
 
  
 
path-
way, which can be mimicked by the addition of calcium
ionophore (ionomycin). As a step toward the identification
of the HDAC7-specific kinase that is activated in thy-
mocytes in response to TCR signaling, we assessed the sub-
cellular localization of HDAC7 after various treatments. For
this purpose, we stably transduced T cell hybridoma cells
(DO11.10) with a HDAC7-GFP construct. In compliance
with our previous results, we observed that unstimulated
DO11.10 cells showed predominantly nuclear HDAC7,
whereas treatment with anti-CD3 antibodies or a combina-
tion of PMA and ionomycin induced exclusion of HDAC7
from the nucleus (Fig. 1 A). Surprisingly, upon treatment
with ionomycin alone, HDAC7 remained nuclear in most
cells (Fig. 1 A). On the other hand, treatment of cells with
PMA alone led to the complete exclusion of HDAC7 from
the nucleus in the vast majority of cells (Fig. 1 A). These re-
sults indicate that the phosphorylation-dependent nuclear
exclusion of HDAC7 upon TCR stimulation does not in-
volve the CaMKs previously implicated in class IIa shuttling
and suggest a role for a PKC-dependent pathway.
To further characterize the TCR-induced HDAC7 ki-
nase, we tested the ability of various inhibitors to interfere
with the nuclear exclusion of HDAC7 upon PMA treatment
(Fig. 1 B). Staurosporine, a general serine/threonine kinase
inhibitor, abolished the nuclear exclusion of HDAC7 by
PMA (Fig. 1 B). Surprisingly, two PKCs inhibitors selective 
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for classical and novel isoforms, GF109203x and Ro-31-
8220, were ineffective at blocking PMA-induced cytoplas-
mic translocation of HDAC7. On the other hand, treatment
with Gö6976, an inhibitor of classical PKCs and PKD, to-
tally prevented the nuclear exclusion of HDAC7 by PMA
treatment (Fig. 1 B).
All together, these results suggest that PKD could be in-
volved in the TCR-induced nuclear exclusion of HDAC7.
 
PKD is activated by TCR signaling in thymocytes
 
If PKD is involved in the nuclear exclusion of HDAC7,
then TCR signaling would be expected to activate PKD in
DO11.10 cells. Autophosphorylation of serine 916 follows
activation of PKD and can thus be used as a marker for PKD
activity (20). We used an antibody specific for phosphory-
lated serine 916 of PKD to monitor the activation of PKD in
DO11.10 cells after various stimuli. As shown in Fig. 2 A,
unstimulated cells exhibited low basal activity of PKD that
was dramatically enhanced upon triggering of the TCR with
an anti-CD3 antibody. Stimulation of cells with a combina-
tion of PMA and ionomycin or PMA alone enhanced even
further the activity of PKD.
Translocation of HDAC7 from the nucleus to the cyto-
plasm occurs within minutes after TCR signaling (11). To
monitor the kinetic of PKD activation, we stimulated
DO11.10 cells with PMA and detected active PKD at differ-
ent time points (Fig. 2 B). As expected, PMA induced a
marked increase in PKD activation compared with basal lev-
els. This activation was maximal within 2 min of stimulation
and was sustained for up to 2 h.
These results indicate that PKD is activated by the
same extracellular signals that induce nuclear exclusion of
Figure 1. TCR-induced nuclear export of HDAC7 is mediated by a 
PMA-stimulated and Gö6976-sensitive kinase. (A) Polyclonal DO11.10 
cells stably expressing HDAC7-GFP were untreated or treated with anti-CD3 
antibodies, PMA and ionomycin, ionomycin, or PMA. Subcellular localization 
of GFP-HDAC7 was monitored by confocal microscopy after 2 h of treat-
ment. Bar histograms represent the mean percentages of cells showing 
nuclear exclusion of HDAC7-GFP in each condition. (B) Polyclonal DO11.10 
cells stably expressing HDAC7-GFP were treated with PMA with or without 
previous incubation with the indicated inhibitors. After 2 h of PMA treat-
ment, localization of HDAC7 was then examined using confocal micros-
copy. Bar histograms represent the mean percentages of cells showing 
nuclear exclusion of HDAC7-GFP in each condition. 
PKD IS INVOLVED IN TCR-INDUCED APOPTOSIS | Dequiedt et al.
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HDAC7 and suggest that PKD could be the kinase regulat-
ing this process in T cells.
 
PKD associates with the amino terminus of HDAC7
 
Subcellular localization of HDAC7 is controlled by phos-
phorylation of three serine residues (S155, S318, and S449)
located in its amino-terminal domain (11, 17). In an attempt
to identify the HDAC7 kinase(s), we expressed the NH
 
2 
 
ter-
minus of HDAC7 (1–490) as a glutathione 
 
S
 
-transferase
(GST) fusion protein in 
 
Escherichia coli
 
. As expected, no
kinase activity could be detected in the GST-HDAC7Nter
or GST alone recombinant protein preparations (Fig. 3
A, 
 
  
 
Extract). To test whether the NH
 
2 
 
terminus of
HDAC7 might recruit kinase activity, we bound the GST-
HDAC7Nter to glutathione agarose beads and incubated
them with extract from DO11.10 cells. After extensive
washing, the bound material was assessed for kinase activity
by in vitro kinase (IVK) assay. High kinase activity was
found associated with GST-HDAC7Nter, but not with the
GST control (Fig. 3 A, 
 
  
 
Extract). To further refine these
observations, IVK reactions were resolved by SDS-PAGE
and analyzed by autoradiography. As shown in Fig. 3 A, a
radioactive band corresponding to GST-HDAC7Nter was
readily detected (Fig. 3 A, 
 
  
 
Extract, bottom). These results
demonstrate that a kinase that can specifically associate with
and phosphorylate the amino terminus of HDAC7 is present
in extracts from DO11.10 cells.
Because our observations so far suggested a role for PKD
in the TCR-induced nuclear exclusion of HDAC7, we
tested if PKD could participate in the kinase activity associ-
ated with HDAC7Nter. Western blot analysis of the bound
material revealed that endogenous PKD1 was specifically
Figure 2. PKD is expressed and activated by TCR in thymocytes. 
(A) DO11.10 cells were left unstimulated (n/s) or stimulated for 15 min 
with anti-CD3 antibodies, PMA and ionomycin, PMA alone, or ionomycin 
alone. Total protein extracts were analyzed by Western blotting with an 
antibody specific for phosphorylated serine 916 of PKD1 (pPKD1, which 
recognizes active PKD1). As a control, the same membrane was stripped 
and probed with an antiserum against total PKD1. (B) DO11.10 cells were 
cultured in the presence of 10 ng/ml PMA, and activation of PKD1 was 
examined at 0, 2, 5, 15, 30, 120, and 240 min by Western blot using the 
phosphorylated serine 916–specific antibody. The same blot was probed 
with an antibody for total PKD1 as control.
Figure 3. PKD associates with the NH2 terminus of HDAC7. (A) The 
NH2 terminus of HDAC7 (aa 1–490) was expressed as a GST fusion protein 
and immobilized on glutathione agarose beads. GST protein alone was 
used as control. Before (  Extract) and after (  Extract) incubation of 
equal amounts of the fusion proteins with total cellular extracts from un-
stimulated, actively growing DO11.10 cells, associated kinase activity was 
revealed by IVK. Total incorporated radioactivity was quantified by scintil-
lation counting. Results representative of three independent experiments 
are shown as a histogram (top). In parallel, IVK assays were analyzed by 
SDS-PAGE and autoradiography (bottom). (B) Pull-downs were analyzed 
for the presence of endogenous PKD1, PKC family members (PKC), and 
activated PKD1 (pPKD1) by Western blot. 
JEM VOL. 201, March 7, 2005
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present in the fraction associated with the NH
 
2 
 
terminus of
HDAC7 but not with GST alone (Fig. 3 B, 
 
 
 
-PKD1). As a
control for specificity, no association with PKC family
members could be detected (Fig. 3 B, 
 
 
 
-PKC). To demon-
strate that PKD could contribute to the HDAC7Nter-spe-
cific kinase activity, we next tested the presence of active
PKD in the material associated with GST-HDAC7Nter.
Western blot analysis with the antibody against active PKD1
revealed that GST-HDAC7Nter was associated with endog-
enous active PKD1 (Fig. 3 B, 
 
 
 
-pPKD1).
 
PKD phosphorylates the amino-terminal domain of HDAC7
 
Next, we examined whether PKD could directly phosphor-
ylate the NH
 
2 
 
terminus of HDAC7. The N- (amino acids
[aa] 1–490) or the COOH-terminal (aa 490–915) domains
of HDAC7 were expressed as GST fusion proteins and incu-
bated with active recombinant PKD1 in an IVK assay. SDS-
PAGE analysis showed incorporation of high levels of the
 
 
 
[
 
32
 
P] label on GST-HDAC7Nter, indicating that it was
very efficiently phosphorylated by PKD in vitro (Fig. 4 A,
GST-HDAC7Nter). In contrast, PKD did not efficiently
phosphorylate GST-HDAC7Cter in a similar assay (Fig. 4 A,
GST-HDAC7Cter).
A peptide library study previously revealed that PKD
prefers a basic residue at position 
 
 
 
3 and is highly selective
for a leucine at position 
 
 
 
5 with respect for the phosphory-
lated serine (21). In silico analysis of the sequences corre-
sponding to the NH
 
2 
 
terminus of HDAC7 revealed four pu-
tative PKD phosphorylation sites located at S155, S181,
S321, and S449 (Fig. 4 B). Remarkably, we had previously
identified three of these serines, S155, S321 and S449, as
crucial for the TCR-induced nuclear exclusion of HDAC7
(11). In addition, considering that the nucleo-cytoplasmic
shuttling of class IIa HDACs is dependent on the binding of
14-3-3 proteins, it is very striking to note that the identified
PKD sites also match the consensus for 14-3-3 binding
R/KXXpSXP, in which pS means phosphoserine (17). To-
gether, these findings strongly suggest that PKD could phos-
phorylate HDAC7 on S155, S181, S321, and S449. To test
this hypothesis, we expressed the HDAC7 sequences sur-
rounding each putative PKD site as GST fusion proteins
(GST-S155, GST-S181, GST-S321, and GST-S449, respec-
tively) and examined their ability to be phosphorylated by
PKD1 in vitro. Mutant fusion proteins with respective serine
to alanine substitutions were used as controls. As shown in
Fig. 4 C, wild-type fusion proteins were very efficiently
phosphorylated by recombinant active PKD (Fig. 4 C, top,
GST-S155, GST-S181, GST-S321, and GST-S449). In ad-
dition, substitutions to alanine abolished phosphorylation
completely, indicating that phosphorylation occurred specif-
ically on Ser155, Ser181, Ser321, and Ser449 (Fig. 4 C, top,
GST-A155, GST-A181, GST-A321, and GST-A449).
Taken together, these data strongly suggest that HDAC7
might be a physiologically relevant substrate for PKD1.
 
PKD overcomes HDAC7-mediated repression of Nur77 
expression
 
If the phosphorylation sites we have identified in HDAC7
are relevant targets for PKD, then PKD would be expected
to alter the subcellular localization of HDAC7. To test this
Figure 4. PKD1 phosphorylates S155, S181, S321, and S449 of 
HDAC7 in vitro. (A) The C- (aa 490–915) and N- (aa 1–490) terminal do-
mains of HDAC7 were produced as GST fusion proteins (GST-HDAC7Cter 
and GST-HDAC7Nter, respectively) and immobilized on glutathione beads. 
Equal amounts of purified recombinant proteins were used in IVK assays 
with constitutively active recombinant PKD1. IVK reactions were analyzed 
by SDS-PAGE and Coomassie staining (left) before autoradiography (right). 
(B) Sequences around the four identified serines in HDAC7 match with the 
canonical PKD recognition motif. (C) GST fusion proteins corresponding to 
the sequences surrounding the four putative PKD phosphorylation sites in 
HDAC7 were used as substrates in independent IVK assays with constitu-
tively active recombinant PKD1. Mutant fusion proteins harboring a serine 
to alanine substitution were used as controls. Reactions were resolved by 
SDS-PAGE and gel was stained with Coomassie, dried, and analyzed by 
autoradiography. The arrow indicates the radioactive band corresponding 
to autophosphorylated PKD1 (rPKD1). 
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possibility, we cotransfected GFP-HDAC7 and a constitu-
tively active mutant of PKD in DO11.10 cells and examined
the localization of HDAC7 by confocal microscopy (Fig. 5
A). As expected, HDAC7 was located mainly in the nucleus
in the absence of active PKD1. In contrast, coexpression of
active PKD1 induced nuclear export of HDAC7, similar to
TCR signaling (Fig. 5 A).
We have previously shown that HDAC7 inhibits Nur77
expression and that this inhibitory action is controlled by its
subcellular localization (11). As PKD promotes nuclear ex-
port of HDAC7, we investigated whether PKD would over-
come the inhibitory activity of endogenous HDAC7 on the
Nur77 promoter and activate its transcription in the absence
of TCR signaling. We first examined the effect of PKD1 on
the transcriptional activity of the isolated Nur77 promoter in
a reporter assay. Constitutively active PKD1 led to a dose-
dependent activation of the transfected Nur77 promoter up
to about fourfold (Fig. 5 B). For comparison, the PMA-
mediated transcriptional activation of the Nur77 promoter in
the absence of constitutively active PKD1 was eightfold. To
confirm these results, we next evaluated the ability of PKD
to activate expression of endogenous Nur77. We observed
that constitutively active PKD1 induced a fivefold induction
of a Nur77-responsive promoter (pNBRE-Luc) after trans-
fection (Fig. 5 C, black bars). Control treatment with PMA
alone led to a ninefold induction of endogenous Nur77 ac-
Figure 5. PKD activation is associated with HDAC7 nuclear export 
and derepression of the Nur77 promoter. (A) DO11.10 cells were trans-
fected with an expression vector encoding GFP-HDAC7 in the absence or 
presence of a plasmid for activated PKD1. Subcellular localization of 
HDAC7 was examined by confocal microscopy. (B) Increasing amounts of 
an expression vector for activated PKD1 were cotransfected with a luciferase 
reporter plasmid driven by the Nur77 promoter (pNur77-Luc) into 
DO11.10 cells. The activity of the Nur77 promoter is shown relative to its 
basal activity, measured in the absence of activated PKD1 using dual lu-
ciferase assay. Luciferase activities were measured in untreated ( ) cells 
or cells treated with PMA for 4 h ( ). Results are from at least three inde-
pendent experiments each performed in triplicate. (C) DO11.10 cells were 
cotransfected with Nur77-responsive reporter constructs pNBREwt-Luc 
(black bars) or pNBREmut-Luc (gray bars) along with an expression vector 
for active PKD1. Luciferase activities are presented relative to the basal 
luciferase activity of pNBREwt-Luc, measured in the absence of active 
PKD1 using the dual luciferase assay. Luciferase activities were measured 
in untreated ( ) cells or cells treated with PMA for 4 h ( ). Results are 
from at least three independent experiments each performed in triplicate.
Figure 6. Repression of PKD is associated with reduced Nur77 pro-
moter activity. (A) DO11.10 cells were left unstimulated (n/s) or treated 
with PMA with or without ( ) previous incubation with the indicated in-
hibitors. After 2 h of PMA treatment, total cellular extracts were prepared 
and analyzed by Western blotting with antisera for activated PKD1 (pPKD1), 
Nur77, and actin. (B) DO11.10 cells were transfected with pNur77-Luc and 
increasing amounts of an expression vector coding for a dominant nega-
tive mutant of PKD1. 40 h after transfection, cells were left unstimulated 
( ) or activated with PMA for 4 h ( ). The activity of the Nur77 promoter 
is shown relative to its activity after PMA treatment in the absence of dom-
inant negative PKD1 measured with the dual luciferase assay. Results are 
from three independent experiments each performed in triplicate. 
JEM VOL. 201, March 7, 2005
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tivity. In addition, an NBRE-luc construct containing mu-
tated Nur77 binding sites was only marginally affected by ac-
tive PKD or PMA treatment (Fig. 5 C, gray bars).
To further demonstrate that PKD is involved in the con-
trol of Nur77 expression, we examined the capacity of
chemicals inhibitors of PKD to interfere with the TCR-
mediated activation of the endogenous Nur77 promoter. The
Nur77 protein is not expressed in DO.11.10 cells but was
highly induced by PMA treatment (Fig. 6 A, middle). PKD1
activation was observed concomitantly, confirming our pre-
vious observations (Fig. 6 A, top). Strikingly, treatment of
cells with staurosporine or Gö6976 markedly impaired acti-
vation of PKD1 and concomitantly noticeably reduced
Nur77 induction. In contrast, Ro-318220 and GF109203x,
which have no effect on PKD, did not interfere with Nur77
activation.
To independently demonstrate that PKD1 is involved in
TCR-induced activation of Nur77, we assessed the effect of
specific PKD1 inhibition on the transcriptional activity of
the Nur77 promoter. As expected, PMA treatment led to a
10-fold increase in the activity of the transfected Nur77 pro-
moter. This activation was inhibited in a dose-dependent
manner by expression of a dominant negative mutant of
PKD1 (Fig. 6 B).
Together, these data suggest that PKD participates in
TCR-induced Nur77 expression by interfering with the in-
hibitory activity of HDAC7.
 
PKD mediates TCR-induced Nur77 expression and apoptosis
 
PKD is uniquely selective for substrates with a leucine res-
idue at position 
 
 
 
5 relative to the phosphorylated serine
(21). To demonstrate that PKD is the specific TCR-acti-
Figure 7. PKD regulates Nur77 expression in response to TCR stim-
ulation. (A) GST fusion proteins corresponding to the sequences surrounding 
the four putative PKD phosphorylation sites in HDAC7 were used indepen-
dently as substrates in IVK assays with constitutively active recombinant 
PKD1. Corresponding mutant fusion proteins, harboring a leucine to alanine 
substitution at position  5 relative to the phosphorylated serine, were 
tested in parallel. IVK reactions were resolved by SDS-PAGE. The gel was 
stained with Coomassie, dried, and analyzed by autoradiography. The arrow 
indicates the radioactive band corresponding to autophosphorylated 
PKD1. (B) Polyclonal DO11.10 cells stably expressing wild-type HDAC7 
(HDAC7wt) or the L150/176/316/444A HDAC7 mutant (HDAC7 L), both 
fused to GFP, were treated with PMA. Subcellular localization of fluorescent 
proteins was monitored by confocal microscopy after 2 h of treatment. 
Bar histograms represent the mean percentages of cells showing nuclear 
exclusion. (C) Polyclonal DO11.10 cell lines, stably expressing FLAG-tagged 
versions of HDAC7 (wt) and the HDAC7 mutant (HDAC7 L) or the
empty vector (Empty), were left unstimulated ( ) or stimulated with PMA 
( ) for 1. 5 h. Total cellular extracts were prepared and analyzed by West-
ern blotting with antisera specific for FLAG, Nur77, and actin. (D) DO11.10 
cells were transfected with the pNur77-Luc reporter construct and the 
same quantity of empty vector (Mock), wild-type HDAC7 (WT), or the  L 
mutant ( L). Luciferase activity was measured in cells treated with PMA 
(left,  ) or ionomycin (right,  ) and untreated cells ( ). The activity of 
the Nur77 promoter is expressed relative to its activity in the mock-
transfected cells after PMA (left) or ionomycin (right) treatment as 
measured by dual luciferase assay. Results are from three independent 
experiments each performed in triplicate. 
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vated kinase of HDAC7, we first examined the role of
these critical leucine residues in the in vitro phosphoryla-
tion of HDAC7 by PKD. HDAC7 sequences centered on
each phosphorylatable serine, S155, S181, S321, and S449,
were expressed as GST fusion proteins (GST-L150, GST-
L176, GST-L316, and GST-L444, respectively) along
with the corresponding mutant fusion proteins, in which
the 
 
 
 
5 leucine was substituted with an alanine (GST-
A150, GST-A176, GST-A316, and GST-A444, respec-
tively). As expected, wild-type fusion proteins were effi-
ciently phosphorylated by recombinant active PKD (Fig. 7
A, top). Single substitution of the 
 
 
 
5 leucine to alanine
dramatically decreased phosphorylation by PKD of S181,
S321, and S449 (Fig. 7 A, top). Surprisingly, mutation of
L150 into A150 had little to no effect on phosphorylation
of S155 by PKD.
Based on these results, we generated an HDAC7 mu-
tant specifically deficient for phosphorylation by PKD
(HDAC7
 
 
 
L) in which the leucine residues at position 
 
 
 
5 of
each phosphorylated serines (namely L150, L176, L316, and
L444) were mutated into alanines. To then assess the subcel-
lular localization of the 
 
 
 
L mutant protein upon PMA acti-
vation, we generated polyclonal DO11.10 cell lines stably
expressing a HDAC7
 
 
 
L-GFP construct. In unstimulated
cells, HDAC7
 
 
 
L localized mainly in the nucleus (not de-
picted), similar to wild-type HDAC7. Although HDAC7
was efficiently exported out of the nucleus upon treatment
with PMA, the HDAC7
 
 
 
L mutant remained nuclear in re-
sponse to the same treatment (Fig. 7 B).
Nuclear exclusion of HDAC7 is a prerequisite for
Nur77 expression (11). Therefore, we would expect the
HDAC7
 
 
 
L mutant to exhibit stronger repression over the
Figure 8. PKD regulates TCR-mediated apoptosis. (A) Polyclonal 
DO11.10 cells lines, stably expressing wild-type HDAC7 (WT), HDAC7 L 
( L), or the empty vector (Mock) were left untreated or treated with PMA/
ionomycin, anti-CD3 antibodies, or cycloheximide (CHX) for 20 h. Apop-
totic cells were detected by PE–annexin V staining and flow cytometry. 
Flow histograms illustrate the percentages of apoptotic cells detected in 
one representative experiment. (B) Mean apoptotic rates from nine inde-
pendent experiments (as described in A) performed from three indepen-
dently established set of polyclonal cell lines are shown. Results are 
expressed relative to the apoptotic rate observed in the mock-transduced 
cell line and are shown as histograms. 
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Nur77 promoter. To verify this hypothesis, we established
polyclonal cell lines by infecting DO11.10 cells with a retro-
virus expressing wild-type HDAC7 or the 
 
 
 
L mutant. En-
dogenous Nur77 expression was analyzed in these cell lines
after PMA treatment. As expected, Nur77 induction was
weakly reduced in cells stably expressing wild-type HDAC7
(Fig. 7 C, middle). Despite being expressed at significantly
lower levels (Fig. 7 C, top), the 
 
 
 
L mutant was associated
with a significantly stronger inhibition of Nur77 expression
(Fig. 7 C, middle). These observations were confirmed using
a Nur77 promoter reporter construct (Fig. 7 D, left). Com-
pared with wild-type HDAC7, the 
 
 
 
L mutant consistently
exhibited a threefold stronger repression effect over PMA-
induced activity of the Nur77 promoter activity (Fig. 7 D,
left). Interestingly, when the Nur77 promoter activity was
induced with ionomycin treatment, the export deficient
mutant HDAC7-
 
 
 
L did not show any additional repressive
effect over wild-type HDAC7 (Fig. 7 D, right).
Next, we reasoned that impairment of HDAC7 phos-
phorylation by PKD should lead to a stronger repression of
TCR-induced apoptosis. We used polyclonal cell lines stably
expressing wild-type HDAC7 or the 
 
 
 
L mutant and mea-
sured their apoptotic rates in response to PMA/ionomycin
or anti-CD3 antibodies (Fig. 8 A). Overexpression of wild-
type HDAC7 weakly inhibited apoptosis induced by PMA/
ionomycin or anti-CD3 antibodies (Fig. 8 A, WT). Consis-
tent with our hypothesis, overexpression of the 
 
 
 
L mutant
was associated with a significantly stronger inhibition of
apoptosis (Fig. 8, A and B, 
 
 
 
L). Importantly, this protective
effect was not observed when cell death was induced with
cycloheximide (Fig. 8 A). Taken together, these data dem-
onstrate that HDAC7 is a physiologically relevant substrate for
PKD1 and strongly support a role for PKD1 in TCR-induced
apoptosis of thymocytes.
 
DISCUSSION
 
During thymic education, negative selection of T cells is as-
sociated with the activation of a specific apoptotic program.
One of the crucial mediators of negative selection in thy-
mocytes and T cell hybridomas is the orphan nuclear recep-
tor Nur77, whose expression is rapidly induced during
TCR-mediated apoptosis. Expression of Nur77 is tightly
controlled by several proteins, amongst which the transcrip-
tion factor MEF2D plays a central role by alternatively
recruiting repressors or activators. We recently identified
HDAC7, a class IIa HDAC, as a major MEF2D-associated
transcriptional repressor of Nur77 in unstimulated thy-
mocytes (11). Derepression of Nur77 and induction of
apoptosis occurs through TCR-mediated phosphorylation of
HDAC7 and subsequent nuclear exclusion. To investigate
the involvement of protein kinases in the TCR-induced nu-
clear exclusion of HDAC7, we used several serine/threonine
protein kinase inhibitors. However, kinase inhibitor studies
should always be regarded with a degree of caution. Indeed,
Gö6976 was also reported to be an efficient inhibitor of
MAPKAP-K1b, MSK1, PKC
 
 
 
, and CHK1, although at a
slightly higher concentration (1 
 
 
 
M; reference 22). Thus,
we resorted to a more specific approach based on the use of a
dominant negative mutant of PKD1. Our results provide
strong evidence that PKD1 contributes to Nur77 expression
by phosphorylating HDAC7 in response to TCR signaling
during negative selection of thymocytes. However, addi-
tional experiments will be required to confirm this model.
Previous work identified KidIns220 (kinase D–interact-
ing substrate of 220 kD), a lipid raft–associated protein selec-
tively expressed in brain and neuroendocrine cells, as an in-
teracting partner and a substrate for PKD (23). However, the
true biological effect of KidIns220 phosphorylation remains
to be elucidated. PKD was also shown to phosphorylate
S351 of the RAS effector RIN1 (24). Interestingly, the au-
thors suggested that phosphorylation of serine 351 by PKD
might create a 14-3-3 binding site in RIN1. Remarkably,
the sequence around S351 of RIN1 (SL
 
346
 
LRSMSAAF354)
perfectly fits with the LXR/KXXS consensus motif that is
also present in the four PKD sites identified in this study in
HDAC7. We and others had previously associated phos-
phorylation of S155, S321, and S449 of HDAC7 with 14-3-3
binding and inactivation through nuclear export (11, 17).
Thus, our findings provide additional evidence that PKD
may function as a regulator of 14-3-3 binding to several cel-
lular proteins. Identification of additional endogenous sub-
strates of PKD should confirm this hypothesis.
It has been proposed that PKD function may also be de-
pendent on the intracellular localization of the kinase (25).
In B cells, antigen receptor stimulation rapidly activates
PKD, which transiently translocates to the plasma membrane
and then redistributes to the cytosol (26). Based on the B cell
model, it is thought that PKD would localize first at the
plasma membrane and then in the cytosol during TCR acti-
vation of T cells. Here, we show that stimulation of the
TCR induces PKD-dependent phosphorylation of a nuclear
protein, HDAC7, which then shuttles from the nucleus to
the cytoplasm. Thus, our results imply that active PKD
would be found, at least in some conditions, in the nucleus
of TCR-stimulated thymocytes. This would be reminiscent
of the nucleo-cytoplasmic shuttling observed for PKD in re-
sponse to G protein–coupled receptor agonists or oxidative
stress (27–29). These mechanisms await further studies to be
fully defined in T cells.
In fibroblast and epithelial cells, PKD has been implicated
in many important cellular processes, including function and
organization of the Golgi apparatus (30–32), normal and tu-
mor cell proliferation (33, 34), cancer cell invasion (35), and
apoptosis (36, 37). Several interesting observations initially
suggested a key role for PKD in lymphoid cells. B cell recep-
tor or TCR engagement rapidly induces activation of PKD
in B cells, peripheral blood T lymphoblasts, and Jurkat cells
(38). However, very little information is available for the true
biological function of PKD in T cells. In this study, we pro-
vide direct experimental evidence supporting a role for PKD
in T cells, where it regulates Nur77 expression and the rate of
apoptosis in response to TCR engagement. Recently, an ele-PKD IS INVOLVED IN TCR-INDUCED APOPTOSIS | Dequiedt et al. 802
gant study used the CD2 promoter and locus control region
to express a membrane- or cytosol-targeted active PKD in
transgenic mice T cells (39). Expression of active PKD in the
cytosol had a dramatic effect on thymocyte cellularity, with
transgenic mice having reduced cell numbers and lacking DP
and single positive (SP) compared with control littermates.
This was partially explained by the capacity of cytosolic PKD
to suppress rearrangement and expression of TCR  subunits,
a mechanism reminiscent of allelic exclusion. However, even
in the presence of a functional TCR complex, cytosolic PKD
prevented development of DP and SP thymocytes (39). This
suggests that expression of constitutively active PKD in the
cytoplasm could perturb thymocyte maturation downstream
of TCR rearrangement. In light of our new findings, this
perturbation could be partially due to an early derepression of
the Nur77 promoter and premature engagement of negative
selection programs in early DP thymocytes. Indeed, the cyto-
solic-targeted PKD used in the transgenic mice study was
generated by deletion of the DAG-binding domain, which
targets the protein to the membrane. One could imagine that
this mutant would retain its capacity to locate to the nucleus
and induces expression of Nur77 in the absence of TCR
stimulation. Interestingly, decreased thymic cellularity, ab-
sence of DP and SP thymocytes, and reduced TCR    ex-
pression were amongst the phenotypes observed in thymi
from Nur77-transgenic mice (8).
Multiple studies have demonstrated the role of Ca2  sig-
naling in TCR-induced transcriptional activation of Nur77
(7, 10, 40). However, published data indicate that Ca2 -
independent pathways also contribute significantly to Nur77
expression (41). At moderate levels, Nur77 mRNA and pro-
tein are rapidly induced in thymocytes stimulated with phor-
bol ester (7). This observation can now be interpreted in
light of our current results. Indeed, activation of PKD by
phorbol ester would induce phosphorylation-dependent nu-
clear export of HDAC7. Subsequently, this would lead to
the establishment of a chromatin environment favorable to
Nur77 transcription and transactivation by other Ca2 -inde-
pendent coactivators such as ERK5 (42). Maximal induction
of Nur77 would require Ca2 -dependent inactivation of ad-
ditional repressors, such as Cabin-1 (10), and recruitment of
Ca2 -dependent (43) coactivators, such as NFAT. This co-
ordinated control through release of repressors and recruit-
ment of coactivators would constitute a tightly regulated
mechanism whereby T cells can activate Nur77 transcription
to a high level in a relatively short time.
The ability of recombinant CaMK to induce class IIa
HDAC nuclear export in transfected cells suggested that
CaMK might be involved in the transduction of extracellular
stimuli through HDAC inactivation (15). CaMKI has been
shown to induce nuclear export of HDAC7 when trans-
fected into Hela cells (17). However, here we provide in
vitro and in vivo experimental evidence that signal-respon-
sive kinases other than CaMKs are involved in this process.
We identified PKD1 as the kinase responsible for the direct
phosphorylation and nuclear exclusion of HDAC7 after
TCR stimulation of thymocytes. Interestingly, in these cells,
activation of the CaMKs with ionomycin did not alter the
subcellular localization of HDAC7, suggesting that HDAC7
is not responsive to the CaMK pathway in T cell hybrid-
omas. This further suggests that class IIa HDACs might be
regulated by different signaling pathways depending on the
cellular context and/or the extracellular stimuli.
Previous data from us and others supported a role for
S155, S321, and S449 in the nuclear exclusion mechanism of
HDAC7 (11, 17). Data presented in this study identified
S181 as an additional phosphorylation site in the amino ter-
minus of HDAC7. Although the role of S181 as a true 14-3-3
binding site remains to be directly tested, sequences flanking
S181 are very similar to those around S321 and S449 and
match the optimal binding motif for 14-3-3. Interestingly,
although S155, S321, and S449 are conserved amongst other
members of the class IIa, S181 is uniquely present in
HDAC7. This could support a model in which each mem-
ber of the class IIa HDAC might be regulated differentially
through phosphorylation.
Intriguingly, all four phosphorylation sites within HDAC7
are not equivalent. We and others have already shown that
S155 was the most critical for HDAC7 nucleo-cytoplasmic
regulation (11, 17). Sequence comparison showed that S155
is the most divergent of the four phosphorylation sites (refer
to Fig. 4). In addition, here we show that S155 in vitro
phosphorylation by PKD1 is uniquely insensitive to an
L150A substitution. The identification of multiple phos-
phorylation sites in HDAC7 and the fact that they present
specific properties raise the interesting possibility that combi-
natorial phosphorylation of these sites would differentially
impact HDAC7 function and regulation.
Class IIa HDACs regulate myogenesis and cardiac hyper-
trophy (18, 19). As PKD had previously been implicated in
cardiac activity (44 and unpublished data) and hypertrophy
(45), it is intriguing to speculate that it could identically con-
trol these biological processes by promoting nuclear export
of class IIa HDACs.
MATERIALS AND METHODS
Plasmids, antibodies, and chemicals. C-terminal GFP proteins of hu-
man HDAC7 were constructed by inserting the full-length HDAC7 ORF
(46) into peGFP-N1 (CLONTECH Laboratories, Inc.) as described previ-
ously (11). The NH2-terminal GST fusion proteins, corresponding to the
NH2 (aa 1–490) and COOH terminus (aa 490–915) of HDAC7 have been
described elsewhere (46). GST-S155, GST-S181, GST-S321, and GST-
S449 constructs contain aa 130–180, 156–216, 267–345, and 396–490, re-
spectively, of HDAC7 cloned into pGEX4T1 (Amersham Biosciences).
Serine to alanine and leucine to alanine substitutions were introduced by
PCR, and mutations were verified by direct DNA sequencing according to
standard methods. The luciferase reporter plasmids driven by the Nur77
promoter (pNur77-Luc) and the wild-type and mutant Nur77-responsive
promoters (pNBREwt-Luc and pNBREmut-Luc) have already been de-
scribed (7, 11). Mammalian expression vectors encoding constitutively ac-
tive (S744E/S748E mutant) and dominant negative (K628N) mutants of
PKD1 have been described (20).
Anti-FLAG, anti-panPKC, and anti-actin antibodies were purchased
from Santa Cruz Biotechnology, Inc. Anti–mouse Nur77 was from BD
Biosciences. Rabbit polyclonal antibodies against PKD1 or PKD1 phos-JEM VOL. 201, March 7, 2005 803
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phorylated at serine 916 were generated by immunization with the KLH-
linked peptides CEEREMKALSERVSIL and CERVpS916IL, respectively.
Phorbol 12-myristate 13-acetate (PMA), ionomycin, and cyclohexi-
mide were purchased from Sigma-Aldrich. Staurosporine, GF109203x, Ro-
31-8220, and Gö6976 were obtained from Qbiogene. Kinase inhibitors
were used at the sublethal concentrations of 200 nM for staurosporine,
GF109203x, and Ro-31-8220 and 400 nM for Gö6976. Cycloheximide
was used at 20  g/ml.
Cell culture, transfections, and reporter assays. DO11.10 T cell hy-
bridomas were maintained in RPMI 1640 medium supplemented with 10%
fetal bovine serum, 2 mM glutamine, and 50 U/ml streptomycin/penicillin.
Transfections were performed by the DEAE-dextran-chloroquine method.
When specified, 10 ng/ml PMA and 0.5  M ionomycin were added sepa-
rately or in combination 40 h after transfection. For anti-CD3 stimulation,
monoclonal antibody 5002A was used as described previously (11). Protein
kinase inhibitors were added 30 min before the stimulation. For reporter as-
says, all transfections were performed in triplicate and are represented as the
mean of at least three independent experiments. Cells were stimulated 4 h
before harvesting, and reporter assays were performed according to the dual
luciferase reporter assay’s recommendations (Promega).
Immunofluorescence. For immunofluorescence experiments, HDAC7-
GFP constructs were transiently transfected or stably transduced into
DO11.10 cells. GFP-expressing cells were left unstimulated or stimulated
with PMA, ionomycin, PMA/ionomycin, or anti-CD3 antibodies in the
presence or absence of the indicated protein kinase inhibitor. Localization
of the fluorescent proteins was assessed by confocal microscopy (Axivert
200 with LSM 510; Carl Zeiss MicroImaging, Inc.). When indicated, the
average percentage of cells showing nuclear exclusion of the GFP-tagged
protein was assessed by examining at least three independent fields each
containing  50 cells.
GST fusion proteins: expression, purification, and pull-downs.
Fusion proteins were expressed in BL21 RIP (Stratagene) and purified ac-
cording to protocols described elsewhere (47). Recombinant, active GST-
PKD1 was produced and purified as described previously (20).
For pull-down reactions, GST fusion proteins were incubated with to-
tal extracts from unstimulated, actively growing DO11.10 cells. After rock-
ing for 3 h at 4 C, reactions were washed three times in IPLS buffer (47),
three times in IPHS buffer (47), and two times in IPLS buffer. Pull-down
reactions were then processed for Western blotting analysis.
IVK assays. Purified GST fusion proteins were incubated with a dilution
of 0.5  g/ml of recombinant active PKD1 in 30  l of phosphorylation mix
containing 10  M ATP, 10  Ci [ -32P]ATP, 25 mM Tris, pH 7.5, and 10
mM MgCl2. After 30 min at 30 C, reactions were terminated by adding an
equal amount of 2  SDS-PAGE sample buffer, and phosphorylated pro-
teins were visualized by SDS-PAGE analysis and autoradiography.
SDS-PAGE and Western blotting. SDS-PAGE and Western blot anal-
ysis were performed according to standard procedures (48). Western blots
were developed with the ECL detection kit (Amersham Biosciences).
Polyclonal cell lines. HDAC7 constructs were cloned into MSCV-based
retroviral vectors without (for HDAC7-GFP constructs) or with (for
HDAC7-FLAG–tagged constructs) an internal ribosome entry site allowing
for simultaneous expression of HDAC7 and enhanced GFP (49). Production
of recombinant infectious particles and infection of DO.11.10 cells were per-
formed as described previously (11). After 48 h, GFP-expressing cells were
sorted by flow cytometry using a FACS Vantage (Becton Dickinson) and ex-
panded. Typically, the polyclonal cell lines contained  99% of GFP  cells.
For apoptosis assay, we used PE-coupled annexin V (BD Biosciences)
according to the manufacturer’s instructions. Cell viability was assessed by
flow cytometry using a FACScan cytometer (Becton Dickinson).
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